Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...

Allergy completes recruitment in grass allergy study, results due ahead of expectations

Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...

Completion of recruitment in PQ Grass Ph II trial

RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...

Hardman Research: Growth in a tough market

RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...

All News

DateHeadlineSource
27-06-17Investor and analyst site visitsRNS
19-06-17Allergy Therapeutics hosts satellite symposium at EAACIStockMarketWire
19-06-17Satellite Symposium at EAACI 2017RNS
06-06-17Directorate changesRNS
02-06-17Holding(s) in CompanyRNS
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire
16-03-17First Patient in Pivotal Phase III Birch StudyRNS
09-03-17Notice of Interim ResultsRNS
14-02-17Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLCStockMarketWire
14-02-17Allergy Therapeutics vaccine gains CTA spprovalStockMarketWire
14-02-17House Dust Mite Allergy Vaccine Gains CTA ApprovalRNS
08-02-17Directorate ChangeRNS
01-02-17Allergy Therapeutics positive data in peanut allergy vaccineStockMarketWire
01-02-17Positive Efficacy & Safety Data in Peanut VaccineRNS
20-01-17Hardman Research: Investment driving market shareRNS
19-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
19-01-17Allergy Therapeutics revenues up StockMarketWire
19-01-17Trading UpdateRNS
09-01-17Top 10 small-cap share tips for 2017Interactive Investor
06-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account